[1] |
GAO Yuan, SHI Wei, XIAO Xiaohe, BAI Zhaofang, WANG Jiabo.
Research progress on the animal models of idiosyncratic drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 33-39.
|
[2] |
SHANG Huiying, WEI Xue, CHENG Hongbo, MA Zengchun, TU Bodan, XIAO Chengrong, LIU Xian, GAO Yue.
Hepatotoxic components in Psoraleae Fructus based on high-content screening technology
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 74-82.
|
[3] |
ZHANG Qin, ZHANG Luyong, JIANG Zhenzhou.
Research progress in safety of PPAR agonists
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 950-955.
|
[4] |
CHEN Linzhen, WANG Xuan, ZHANG Xiaomeng, MA Zhiqiang, LU Shan, WU Jiarui, ZHAO Chongjun, ZHANG Bing.
Evaluation of hepatotoxicity of periplocin based on zebrafish model
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 742-748.
|
[5] |
ZHANG Lei, LYU Jian, XIE Yanming.
Efficacy and safety of Houpupaiqi Mixture in the treatment of postoperative lieus: a Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 799-806.
|
[6] |
HUANG Cuili, GAO Ao, WANG Jiaxi, GUO Haili, XU Xiaohan, CHENG Yinchu, GUO Daihong.
Automatic monitoring and assessment of antibiotics-related thrombocytopenia
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 807-811.
|
[7] |
ZHU Chunwu, YU Xuejun, SUN Xin, LIU Chenghai.
Overview of hepatotoxicity of Xianling Gubao capsules
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 496-499.
|
[8] |
LI Rongrong, LI Meng, GOU Yue, LUO Qiong, LYU Hua, SUN Xin, LIU Chenghai.
Clinical characteristics and risk factors of 113 cases of anti-neoplastic drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 505-510.
|
[9] |
CHENG Fengjingming, LYU Jian, XIE Yanming.
Efficacy and safety of compound salvia miltiorrhiza spray/aerosol for angina pectoris due to coronary artery disease: a Meta analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 536-543.
|
[10] |
LYU Peng, ZHANG Jingli, WANG Yunhong, MA Fenfen, ZHANG Yu, HUANG Yifei.
Risk factors and mechanisms for skin squamous cell carcinoma in lung transplant recipients induced by voriconazole
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 595-600.
|
[11] |
SU Xinxin, LYU Jian, XIE Yanming.
Efficacy and safety of Toutongning capsules in the treatment of chronic headache: a Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 433-440.
|
[12] |
WANG Xiaohui, ZHANG Fan, XIA Wenbin, WEI Yuhui.
Mechanisms of genipin-induced hepatotoxicity by using network pharmacology and transcriptomics
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 177-180.
|
[13] |
WANG Jiaxi, GUO Daihong, ZHANG Bo, Li Boyan, GUO Haili.
Automatic monitoring and risk factors of acute kidney injury in 116097 dosing cases of flurbiprofen axetil
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 201-205.
|
[14] |
WANG Li, YU Wenwen, LI Min, GUO Ruihui, CAO Guangsheng, QI Yingmei.
Risk factors and precautions for adverse drug reactions caused by Digoxin
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1269-1272.
|
[15] |
YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang.
Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.
|